The Golden Age in Cancer Medtech Investing
Article preview reprinted from Start-Up - November 2008
Short of investing in the kinds of products that must demonstrate five-year survival rates, the field of cancer offers many near term investment opportunities, and large markets to support them.
The Golden Age in Cancer Medtech Investing
As noted in US Disease Incidence and Prevalence, a report recently published by the Medtech Insight division of FDC-Windhover, like many diseases, the incidence of cancer increases with age. More than 10.8 million people in the US have a history of cancer; and in 2008, at least 1.4 million more people will be diagnosed. According to the Medtech Insight report, breast cancer has the highest prevalence rate, followed by prostate and colorectal cancers.
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Companies mentioned in this article:
BioImagene Inc.
Calypso Medical Technologies Inc.
Eli Lilly & Co.
ImClone Systems Inc.
Endocare Inc.
Pfizer Inc.
Siemens AG
U-Systems Inc.
Xoft Inc.
superDimension Ltd.
START-UP: No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics. Subscribe to START-UP.
